In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Bucks the Trend

Executive Summary

While many drug companies now see development as key to boosting productivity, Novartis is investing heavily in its own discovery capacity. A new research head has been hiring hot shots out of biotech firms and academia, assembling new technologies to complement classical skills. Novartis seems to be striving to be mostly self-dependent. Will the bet pay off?
Advertisement

Related Content

Big Pharma's Large Molecule Challenge
Big Pharma's Large Molecule Challenge
How Experimental Medicine Is Affecting Big Pharma
How Experimental Medicine Is Affecting Big Pharma
Jumpstart to Products
Jumpstart to Products
R&D Productivity at GSK? He CEDD, She CEDD
Vertex Sells Productivity
Vertex Sells Productivity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel